Literature DB >> 11546668

Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events.

A O Gramolini1, G Bélanger, J M Thompson, J V Chakkalakal, B J Jasmin.   

Abstract

In addition to showing differences in the levels of contractile proteins and metabolic enzymes, fast and slow muscles also differ in their expression profile of structural and synaptic proteins. Because utrophin is a structural protein expressed at the neuromuscular junction, we hypothesize that its expression may be different between fast and slow muscles. Western blots showed that, compared with fast extensor digitorum longus (EDL) muscles, slow soleus muscles contain significantly more utrophin. Quantitative RT-PCR revealed that this difference is accompanied by a parallel increase in the expression of utrophin transcripts. Interestingly, the higher levels of utrophin and its mRNA appear to occur in extrasynaptic regions of muscle fibers as shown by immunofluorescence and in situ hybridization experiments. Furthermore, nuclear run-on assays showed that the rate of transcription of the utrophin gene was nearly identical between EDL and soleus muscles, indicating that increased mRNA stability accounts for the higher levels of utrophin in slow muscles. Direct plasmid injections of reporter gene constructs showed that cis-acting elements contained within the utrophin 3'-untranslated region (3'-UTR) confer greater stability to chimeric LacZ transcripts in soleus muscles. Finally, we observed a clear difference between EDL and soleus muscles in the abundance of RNA-binding proteins interacting with the utrophin 3'-UTR. Together, these findings highlight the contribution of posttranscriptional events in regulating the expression of utrophin in muscle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546668     DOI: 10.1152/ajpcell.2001.281.4.C1300

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  31 in total

1.  Resveratrol induces expression of the slow, oxidative phenotype in mdx mouse muscle together with enhanced activity of the SIRT1-PGC-1α axis.

Authors:  Vladimir Ljubicic; Matthew Burt; John A Lunde; Bernard J Jasmin
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-23       Impact factor: 4.249

2.  Variable cytoplasmic actin expression impacts the sensitivity of different dystrophin-deficient mdx skeletal muscles to eccentric contraction.

Authors:  Angus Lindsay; William M Southern; Preston M McCourt; Alexie A Larson; James S Hodges; Dawn A Lowe; James M Ervasti
Journal:  FEBS J       Date:  2019-04-11       Impact factor: 5.542

Review 3.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

4.  A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.

Authors:  Annamaria De Luca; Beatrice Nico; Antonella Liantonio; Maria Paola Didonna; Bodvael Fraysse; Sabata Pierno; Rosa Burdi; Domenica Mangieri; Jean-François Rolland; Claudia Camerino; Alberta Zallone; Paolo Confalonieri; Francesca Andreetta; Elisa Arnoldi; Isabelle Courdier-Fruh; Josef P Magyar; Antonio Frigeri; Michela Pisoni; Maria Svelto; Diana Conte Camerino
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

5.  Enhanced Ca2+ transport and muscle relaxation in skeletal muscle from sarcolipin-null mice.

Authors:  A Russell Tupling; Eric Bombardier; Subash C Gupta; Dawar Hussain; Chris Vigna; Darin Bloemberg; Joe Quadrilatero; Maria G Trivieri; Gopal J Babu; Peter H Backx; Muthu Periasamy; David H MacLennan; Anthony O Gramolini
Journal:  Am J Physiol Cell Physiol       Date:  2011-06-22       Impact factor: 4.249

6.  Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice.

Authors:  D Gardan-Salmon; J M Dixon; S M Lonergan; J T Selsby
Journal:  Eur J Appl Physiol       Date:  2011-03-16       Impact factor: 3.078

Review 7.  Skeletal muscle fiber type: using insights from muscle developmental biology to dissect targets for susceptibility and resistance to muscle disease.

Authors:  Jared Talbot; Lisa Maves
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2016-05-19       Impact factor: 5.814

8.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

9.  Ets-2 repressor factor silences extrasynaptic utrophin by N-box mediated repression in skeletal muscle.

Authors:  Kelly J Perkins; Utpal Basu; Murat T Budak; Caroline Ketterer; Santhosh M Baby; Olga Lozynska; John A Lunde; Bernard J Jasmin; Neal A Rubinstein; Tejvir S Khurana
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

10.  Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling.

Authors:  Joe V Chakkalakal; Mark A Stocksley; Mary-Ann Harrison; Lindsay M Angus; Julie Deschenes-Furry; Simon St-Pierre; Lynn A Megeney; Eva R Chin; Robin N Michel; Bernard J Jasmin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.